Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
Radiothérapie Moléculaire et Innovation Thérapeutique, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004848.
Strong rationale and a growing number of preclinical and clinical studies support combining radiotherapy and immunotherapy to improve patient outcomes. However, several critical questions remain, such as the identification of patients who will benefit from immunotherapy and the identification of the best modalities of treatment to optimize patient response. Imaging biomarkers and radiomics have recently emerged as promising tools for the non-invasive assessment of the whole disease of the patient, allowing comprehensive analysis of the tumor microenvironment, the spatial heterogeneity of the disease and its temporal changes. This review presents the potential applications of medical imaging and the challenges to address, in order to help clinicians choose the optimal modalities of both radiotherapy and immunotherapy, to predict patient's outcomes and to assess response to these promising combinations.
强有力的理论基础和越来越多的临床前和临床研究支持将放射治疗和免疫治疗相结合，以改善患者的预后。然而，仍有一些关键问题需要解决，例如确定哪些患者将从免疫治疗中受益，以及确定最佳的治疗方式来优化患者的反应。影像学生物标志物和放射组学最近已成为评估患者整个疾病的非侵入性的有前途的工具，允许对肿瘤微环境、疾病的空间异质性及其时间变化进行全面分析。本文综述了医学影像学的潜在应用和需要解决的挑战，以帮助临床医生选择放射治疗和免疫治疗的最佳方式，预测患者的预后，并评估这些有前途的联合治疗的反应。
